Compare IOVA & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IOVA | KBDC |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 941.8M |
| IPO Year | 2008 | 2018 |
| Metric | IOVA | KBDC |
|---|---|---|
| Price | $3.53 | $13.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $10.45 | ★ $15.80 |
| AVG Volume (30 Days) | ★ 9.3M | 342.2K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.89% |
| EPS Growth | ★ 32.28 | N/A |
| EPS | N/A | ★ 1.23 |
| Revenue | N/A | N/A |
| Revenue This Year | $60.04 | $193.84 |
| Revenue Next Year | $58.54 | $9.00 |
| P/E Ratio | ★ N/A | $11.12 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $13.06 |
| 52 Week High | $5.64 | $17.60 |
| Indicator | IOVA | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 77.86 | 42.32 |
| Support Level | $2.11 | $13.52 |
| Resistance Level | $3.73 | $15.25 |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 97.56 | 32.50 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.